OncLive® On Air

In today’s episode, we sat down with Julia Rotow, MD, and Gavitt Woodard, MD, to talk through recent updates to the perioperative non–small cell lung cancer treatment paradigm. 

In today’s episode, we passed the mic to Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD, who led an OncLive Ask the Expert discussion on evolving imaging strategies in glioma. 

In today’s episode, we had the pleasure of speaking with Jason Mouabbi, MD, about the role of circulating tumor DNA (ctDNA) testing in early-stage breast cancer management. Dr Mouabbi is an assistant professor in the Department of Breast Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Mouabbi highlighted the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer, data suggesting that ctDNA negativity after neoadjuvant therapy can be more predictive of long-term outcomes than pathologic complete response, and the importance of offering ctDNA testing to patients and discussing the benefits of this emerging approach.

In today’s episode, we had the pleasure of speaking with Pooja M. Phull, MD, a hematologist/oncologist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, about emerging insights into the gut microbiome and its clinical relevance in multiple myeloma. Dr Phull discussed how microbial composition—particularly the presence of butyrate-producing bacteria—may influence therapeutic responsiveness, sustained minimal residual disease negativity, and long-term outcomes for patients undergoing autologous stem cell transplantation. In our exclusive interview, Dr Phull reviewed findings from a translational study that longitudinally profiled the fecal microbiome of patients with newly diagnosed myeloma, highlighting the significant post-transplant depletion of beneficial short-chain, fatty acid–producing organisms and its association with inferior progression-free survival. She also outlined supportive laboratory and in vivo data demonstrating the antitumor effects of butyrate and discussed how microbiome profiling may serve as both a predictive biomarker and a potential therapeutic target. Additionally, Dr Phull explored how dietary patterns, lifestyle factors, and antibiotic stewardship may contribute to preserving gut microbial health, and she emphasized the growing need for prospective studies to clarify how these interventions could enhance treatment outcomes for patients with active myeloma and precursor conditions such as monoclonal gammopathy of undetermined significance and smoldering myeloma.

In today’s episode, we had the pleasure of speaking with Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH, about the promise of IB6 as a therapeutic target in non–small cell lung cancer (NSCLC) management. Dr Kim is physician-in-chief of City of Hope Orange County, vice physician-in-chief of the City of Hope National Medical Center, and a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Irvine, California. Dr Malhotra is interim division chief of Thoracic Medical Oncology, an associate professor in the Department of Medical Oncology & Therapeutics Research, and the director of Thoracic Medical Oncology at City of Hope. In our exclusive interview, Drs Kim and Malhotra discussed factors that make IB6 unique compared with other NSCLC biomarkers, the prevalence of IB6 expression among patients with lung cancer, and the rationale for investigating sigvotatug vedotin (formerly SGN-B6A) vs docetaxel in patients with previously treated NSCLC in the phase 3 Be6A Lung-01 trial (NCT06012435).